Hillstream Biopharma (NASDAQ:CNTN) Stock Rating Lowered by Wall Street Zen

Hillstream Biopharma (NASDAQ:CNTN) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings began coverage on shares of Hillstream Biopharma in a research note on Monday, March 9th. They set a “sell (e+)” rating on the stock. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Hillstream Biopharma Price Performance

Shares of NASDAQ CNTN opened at $3.26 on Friday. Hillstream Biopharma has a twelve month low of $0.95 and a twelve month high of $9.08. The firm has a market capitalization of $184.71 million, a PE ratio of -0.82 and a beta of 1.57.

Hillstream Biopharma (NASDAQ:CNTN) last posted its earnings results on Tuesday, March 31st. The company reported $0.54 earnings per share (EPS) for the quarter.

Hillstream Biopharma Company Profile

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.